Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases at RSNA 2019. Photo by Dave Fornell
Feature | Radiation Dose Management | Dave Fornell, Editor

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

Home November 04, 2020
Home
The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
News | Pulmonary Embolism

October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world p ...

Home October 23, 2020
Home
News | FFR Technologies

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

Home October 23, 2020
Home
News | FFR Technologies | Dave Fornell, Editor

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
News | Stents

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
Videos | Cath Lab

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Heart Valve Technology

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
Subscribe Now